Analysis: ICICI Lombard General Insurance Company Limited

NSE:ICICIGI Finance - Non Life Insurance Market cap: ₹75.7K cr

Growth thesis

ICICI Lombard remains a compounder because its underwriting gap is wide enough to absorb the Supreme Court motor TP shock without a recurring reserve charge, while retail health and digital distribution add a second growth engine. The business writes motor, health, fire, marine, engineering, liability and crop insurance through agents, bancassurance, brokers and the IL TakeCare app. Motor is the largest line at about 40% of FY2026 GDPI and health about 32%, with commercial lines and government schemes diversifying the book. The economic core is underwriting discipline: FY2026 combined ratio was 103.4% on a 1/n basis against the industry's 117.8%, and the motor gap widened to 21.4 percentage points. In H1 FY2027 the company's combined ratio was 105.2%, or 104.2% excluding CAT losses, still far better than the industry motor combined ratio of 131.4% in Q1 FY2027. The motor loss ratio was 65.4% in H1 FY2027, inside the 65-67% range, even after the June 2026 Supreme Court judgement created a 12-15% industry motor TP loss-ratio headwind. Management took a ₹1.65 billion Q1 FY2027 reserve and by Q2 said the judgement was fully integrated, with no further provision anticipated. That is the key earnings-path change: the old fear was a recurring quarterly charge; the current evidence points to a one-time Q1 hit plus ongoing loss-ratio monitoring. Q2 FY2027 PAT rose 27.5% to ₹10.31 billion and ROE was 23.7%, while H1 PAT fell 5.8% to ₹14.54 billion because Q1 absorbed the Supreme Court and Fire large-loss charges. H1 ROE was 16.8%. Solvency was 2.74x at September 30, 2026, and the interim dividend rose to ₹7 per share from ₹6.5. Investment income was ₹15.54 billion in Q2 versus ₹12.49 billion, and capital gains ₹4.53 billion versus ₹2.36 billion, so the investment book is adding to the recovery rather than offsetting it. The retail health engine is the most important growth milestone. H1 FY2027 health premium grew 26.8% against industry 21%, retail health grew 66.4% against 32%, and market share rose to 4.7% from 3.7%, reaching 5% in September 2026. The long-term book was 53.4% of new retail health business in Q1 FY2027, up from 31.8%, which locks in multi-year premium if the loss ratio stays inside 65-70%. Q2 retail indemnity was 64.6%, inside the range. Group health is less stable: Q2 loss ratio was 97.9% versus 93.7%, after about 99.9% in Q1, but still within the mid-90s threshold management has described. Commercial lines are the cyclical swing factor. Q2 FY2027 commercial lines excluding Fire grew 20%, and H1 grew 13.2%, while Fire de-growth moderated to 21.2% from 32.1% in Q1 and 6% in September. The company gained share in Fire, Marine Cargo, Engineering and Liability. If Fire pricing stabilises, commercial lines can support growth without abandoning discipline. If it does not, the company will keep ceding Fire share rather than write inadequate risk. Distribution reform is a potential structural positive but not yet a delivered benefit. IRDAI's consultation paper proposes an expense-of-management trajectory of 25% at the initial phase and changes to commissions. Management says uniform tightening would favour ICICI Lombard because it has stayed within the 30% limit while roughly 21 of 34 players have not. The same reform could lower Motor TP tariff economics, so the net effect on motor pricing is unresolved. The GST Council's October 8, 2026 recommendation to remove restrictions on input tax credit for group health and life insurance is a smaller positive for employer-sponsored health affordability. Digital distribution is an explicit target, not yet an outcome: management aims to lift digital sourcing from 6% to 15%, supported by 23.3 million IL TakeCare downloads and 73% digital customer-interaction share. Capital allocation is simple and conservative. The company carries solvency well above the 1.50x minimum, pays out roughly a quarter of PAT, and has no disclosed company-funded capex or acquisition programme in the supplied calls. The ₹78 crore arbitration award relates to an old policy, is gross and reinsurance-protected, and the CFO does not expect it to be material net, though legal remedies are still open. Management delivery is mixed but not broken. The motor and health loss-ratio ranges have held, expense of management has stayed within 30%, and the Supreme Court reserve was handled prudently. The growth-outperformance promise has not held on a headline basis: FY2026 grew 7.0% against 9.2%, and H1 FY2027 grew 5.4% against 8.9%, though Q2 excluding crop and mass health grew 13.9% against 13.2%. The Ind AS transition remains an accounting bridge, with the 300-450 bps adoption-year combined-ratio guidance not updated in the Q2 call. The thesis is therefore an operating-leverage compounder with a narrower risk premium than three months ago, not a turnaround. The falsifiers are specific: motor loss ratio sustainably above 67% without a tariff offset; retail health loss ratio above 70% as the book ages; group health staying near 98% rather than the mid-90s; Fire remaining in double-digit de-growth through FY2028; or distribution reform compressing Motor TP tariffs and agency economics. If those do not occur, the combination of a 20+ point motor underwriting gap, a 4.7% and rising retail health share, and a 2.74x solvency ratio can keep ROE in the high teens even while headline GDPI growth lags the industry.

Why is ICICI Lombard General Insurance Company Limited stock rising?

  • The Q2 FY2027 CFO said the June 2026 Supreme Court motor TP judgement is fully integrated and no further reserve provision is anticipated. If that holds, the ₹1.65 billion Q1 charge stays a one-time event rather than a recurring drag, and earnings normalise as motor loss ratios remain inside the 65-67% range.
  • Motor premium grew 13% in H1 FY2027 against industry 13.1%, and the motor loss ratio was 65.4%, inside the stated 65-67% range. Holding that range while the industry motor combined ratio is 131.4% in Q1 FY2027 would show the underwriting gap is intact after the Supreme Court shock.
  • Retail health grew 66.4% in H1 FY2027 against industry 32%, lifting share to 4.7% from 3.7% and reaching 5% in September 2026. The long-term book was 53.4% of new retail health business in Q1 FY2027, which locks in multi-year premium if the loss ratio stays within 65-70%.
  • Commercial lines excluding Fire grew 20% in Q2 FY2027 and 13.2% in H1, while Fire de-growth moderated to 21.2% from 32.1% in Q1 and to 6% in September. If Fire pricing stabilises, the SME and non-Fire commercial mix can support growth without abandoning underwriting discipline.
  • Q2 FY2027 PAT rose 27.5% to ₹10.31 billion and ROE was 23.7%, while H1 PAT fell 5.8% because of the Q1 one-offs. Solvency was 2.74x at September 30 and the interim dividend rose to ₹7 per share, giving room to absorb volatility and still return capital.

Research report

companyname: ICICI Lombard General Insurance Company Limited ticker: ICICIGI sector: General Insurance / Non-Life Insurance ICICI Lombard is one of India's largest private general insurers, formed in 2001 as a joint venture between ICICI Bank and Fairfax Financial Holdings. The company completed 25 years of operations in FY2026, having served over 500 million customers since inception and processed over 60 million claims. It underwrites non-life insurance across Motor, Health, Crop and Weather,...

Read the full report →

Catalysts

market share gain

Growth guidance

Explicit forward guidance in the Q2 FY2027 call is mostly qualitative and range-based: motor is discussed against the 65-67% loss-ratio range, group health against mid-90s and retail health against 65-70%; the Supreme Court motor TP reserve is described as fully integrated with no further provision anticipated; digital sourcing is targeted to rise from 6% to 15%; and growth momentum is expected to continue in Q3 and Q4. No quantitative FY2027 or FY2028 revenue, margin or ROE guidance is given in this call.

Guidance maintained

Management consistency

consistent

RS rating: 47 Stage: Stage 4

Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for ICICI Lombard General Insurance Company Limited and 4,900+ companies.

Sign in
5-day free pass. No card required.